You can buy or sell ALIM and other stocks, options, ETFs, and crypto commission-free!
Alimera Sciences, Inc. engages in the research and development of biopharmaceutical products. It operates through the U.S. and International geographic segments. Read More The firm focuses on the development of ophthalmic pharmaceuticals for the treatment of diabetic macular edema, wet and dry age-related macular degeneration, and retinal vein occlusion. Its products include ILUVIEN and NADPH Oxidase Inhibitors. The company was founded by Daniel C. Myers and David R. Holland on June 4, 2003 and is headquartered in Alpharetta, GA.
52 Week High
52 Week Low
Research And Development
Markets InsiderMar 14
EyePoint Pharmaceuticals Reports Fiscal Period Ended December 31, 2018 Financial Results and Highlights Recent Clinical and Operational Developments
-YUTIQ™ and DEXYCU™ commercially launched in 1Q2019- -$60 million debt facility secured to support YUTIQ and DEXYCU commercial launches- -Conference call and webcast today, March 14, at 8:30 a.m. ET- WATERTOWN, Mass., March 14, 2019 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a specialty biopharmaceutical company committed to developing and commercializing innovative ophthalmic products, today reported financial results for the three and six-month fiscal period ended December 31,...
Yahoo FinanceMar 6
Alimera Sciences Announces the Reimbursement of ILUVIEN(R) in France
France is a Significant Market for Intravitreal Steroid Use ATLANTA, GA / ACCESSWIRE / March 6, 2019 / Alimera Sciences, Inc. (ALIM) (Alimera), a leader in the commercialization and development of prescription ophthalmic pharmaceuticals, today announced that its subsidiary, Alimera Sciences Limited, received a positive resolution for the pricing and reimbursement approval for ILUVIEN® from Comité Economique des Produits de Santé (CEPS). This means that in France, ILUVIEN will be fully reimbursed for use in...
Stock Price, News, & Analysis for Alimera Sciences
Alimera Sciences, Inc., a pharmaceutical company, engages in the research, development, and commercialization of prescription ophthalmic pharmaceuticals in the United States and internationally. It focuses on diseases affecting the back of the eye or retina. The company offers ILUVIEN, an intravitreal implant for the treatment of diabetic macular edema (DME), which is a disease of the retina that affects individuals with diabetes and could lead to severe vision loss and blindness. Its ILUVIEN is inserted in...
Expected May 1